LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio celebrates its inaugural Healthcare BioForum

06/10/2022
PRESS RELEASE
Brussels, 6 October 2022

On 5 October 2022, EuropaBio held its first Healthcare BioForum to discuss how innovation, investment and excellence in healthcare biotechnology can help to achieve a competitive environment in Europe. The high-level policy event brought together EuropaBio members and representatives of the EU institutions who exchanged on how to realise Europe’s full potential for healthcare biotechnology in the context of the Pharmaceutical Strategy for Europe.

‘We were delighted to bring together members and EU policymakers at our inaugural Healthcare BioForum and discuss how the EU can lead other regions in the world. In the context of global challenges that we face and amazing advances in science, a revision of the pharmaceutical legislation is a pivotal moment which will define how the EU addresses the health needs of Europeans from a thriving healthcare biotechnology sector. Our new Forum will serve as a platform for future discussions and understanding between companies, including SMEs, and policymakers.’ said Dr Claire Skentelbery, Director General of EuropaBio.

The discussions highlighted the importance of dialogue and collaboration between industry and policymakers to make Europe an attractive and prosperous ecosystem for healthcare biotechnology. Participants also raised the need to improve Europe’s regulatory efficiency to close the gap with other regions and accelerate the timeframe for bringing medicines from bench to patients.

The discussions also revealed the necessity for stability and predictability to attract investments in Europe and to continue to bridge the gap between basic research and clinical development. In addition, participants agreed on the need for foster the EU’s complex and fragile innovation ecosystem that brings together academia, SMEs, and innovative pharmaceutical companies. The Forum concluded with an outlook for Europe’s healthcare biotechnology in 2030.

The event report with outcomes and recommendations will be published over the coming weeks.

EuropaBio celebrates its inaugural Healthcare BioForum


Download
2022_10_H_PR_EuropaBio-Healthcare-BioForumDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.